Four types of AA deamination transamination oxidative deamination

  • Slides: 42
Download presentation

Four types of AA deamination: transamination oxidative deamination union deamination non-oxidative deamination

Four types of AA deamination: transamination oxidative deamination union deamination non-oxidative deamination

Source and outlet of NH 3 1. Sources: ⑴ Endogenous sources: ① Deamination of

Source and outlet of NH 3 1. Sources: ⑴ Endogenous sources: ① Deamination of AAs--main source ② Other nitrogen containing compounds ③ Kidney secretion (Gln) NH 3+H+ NH 4

⑵ Exogenous sources: ① Putrefaction in the intestine. ② Degradation of urea in the

⑵ Exogenous sources: ① Putrefaction in the intestine. ② Degradation of urea in the intestine NH 3+H+ NH 4

2. Outlets: (1) Formation of urea (2) Formation of Gln (3) Excrete in urine

2. Outlets: (1) Formation of urea (2) Formation of Gln (3) Excrete in urine (4) Synthesis of AA

Summary

Summary

One carbon units are carried by FH 4

One carbon units are carried by FH 4

Transmethylation and Met cycle

Transmethylation and Met cycle

PBG Heme ALA dehydratase ALA synthase ferrochelatase Gly succinyl Co. A Linear tetrapyrrol Protoporphyrin

PBG Heme ALA dehydratase ALA synthase ferrochelatase Gly succinyl Co. A Linear tetrapyrrol Protoporphyrin Ⅸ Protoporphyrinogen Ⅸ CPGⅢ UPGⅢ

coenzyme -pyridoxal phosphate ① ALA synthase ② decarboxylase ③ transaminase

coenzyme -pyridoxal phosphate ① ALA synthase ② decarboxylase ③ transaminase

1. Formation and transport of bilirubin *The source of bilirubin The compounds involving iron

1. Formation and transport of bilirubin *The source of bilirubin The compounds involving iron prophyrin in the body are hemoglobin, myoglobin, cytochrome, peroxidase, and catalase, etc.

 • Formation of bilirubin

• Formation of bilirubin

hydrophobic

hydrophobic

structure of bilirubin diglucuronide Carbosyl group Hydroxyl group

structure of bilirubin diglucuronide Carbosyl group Hydroxyl group

Jaundice • Hemolytic (prehepatic) jaundice • Hepatocellular (hepatic) jaundice • Obstructive (posthepatic) jaundice

Jaundice • Hemolytic (prehepatic) jaundice • Hepatocellular (hepatic) jaundice • Obstructive (posthepatic) jaundice

Laboratory results in patients with jaundice normal Hemolytic jaundice < 1 mg/dl > 1

Laboratory results in patients with jaundice normal Hemolytic jaundice < 1 mg/dl > 1 mg/dl Hepatocellular jaundice Obstructive jaundice Serum bilirubin total direct ↑ 0~ 0. 8 mg/dl indirect <1 > 1 mg/dl ↑↑ ↑ – ++ > 1 mg/dl ↑↑ Urine bile pigments urobilirubin – ++ urobilinogen A few ↑ uncertainty ↓ urobilin A few ↑ uncertainty ↓ Color of feces normal dark Simple or normal Clay color

two pathways of nucleotides De novo synthesis: precursors: amino acids, ribose-5 phosphate, CO 2,

two pathways of nucleotides De novo synthesis: precursors: amino acids, ribose-5 phosphate, CO 2, and one-carbon units. Salvage pathways: recycle the free bases or nucleosides.

Purine De novo synthesis a. Purines are synthesized using 5 phosphoribose as the starting

Purine De novo synthesis a. Purines are synthesized using 5 phosphoribose as the starting material step by step. b. PRPP is active donor of R-5 -P. c. AMP and GMP are synthesized further at the base of IMP.

Pyrimidine De novo synthesis • The pyrimidine ring is first synthesized, then combines with

Pyrimidine De novo synthesis • The pyrimidine ring is first synthesized, then combines with PRPP. • UMP is first synthesized, then UMP is used for synthesizing other pyrimidine nucleotides.

Element sources of purine bases

Element sources of purine bases

Element source of pyrimidine

Element source of pyrimidine

Regulation of de novo synthesis of purine nucleotides

Regulation of de novo synthesis of purine nucleotides

Summary of purine biosynthesis IMP Deoxyribonucleotide

Summary of purine biosynthesis IMP Deoxyribonucleotide

Summary of pyrimidine biosynthesis UMP

Summary of pyrimidine biosynthesis UMP

Catabolism of Purine Nucleotides

Catabolism of Purine Nucleotides

 • Elevated concentration of uric acid cause gout. • Crystals of sodium urate

• Elevated concentration of uric acid cause gout. • Crystals of sodium urate deposited in the joints and the kidney tubules.

Allopurinol – a suicide inhibitor used to treat Gout

Allopurinol – a suicide inhibitor used to treat Gout

Antimetabolites of nucleotides • structural analogs of purine, amino acids and folic acid. They

Antimetabolites of nucleotides • structural analogs of purine, amino acids and folic acid. They can interfere, inhibit or block synthesis pathway of purine nucleotides and further block synthesis of RNA, DNA, and proteins.

Competitive inhibition

Competitive inhibition

inhibitor • structural similarities with substrates. • compete for the active sites with S.

inhibitor • structural similarities with substrates. • compete for the active sites with S.

Feed back inhibition

Feed back inhibition

1. 1 Purine analogs • 6 -Mercaptopurine (6 -MP) is a analog of hypoxanthine.

1. 1 Purine analogs • 6 -Mercaptopurine (6 -MP) is a analog of hypoxanthine.

 • 6 -MP nucleotide is a analog of IMP de novo synthesis -

• 6 -MP nucleotide is a analog of IMP de novo synthesis - amidotransferase - 6 -MP IMP 6 -MP nucleotide - AMP and GMP - HGPRT - salvage pathway

1. 2 Pyrimidine analogs • 5 -fluorouracil (5 -FU) is a analog of thymine.

1. 2 Pyrimidine analogs • 5 -fluorouracil (5 -FU) is a analog of thymine.

d. UMP 5 -FU d. TMP 5 -Fd. UMP 5 -FUTP Synthesis of RNA

d. UMP 5 -FU d. TMP 5 -Fd. UMP 5 -FUTP Synthesis of RNA Destroy structure of RNA

2. Amino acid analogs • Azaserine (AS) is a analog of Gln.

2. Amino acid analogs • Azaserine (AS) is a analog of Gln.

3. Folic acid analogs • Aminopterin (AP) and Methotrexate (MTX)

3. Folic acid analogs • Aminopterin (AP) and Methotrexate (MTX)

4. Nucleoside analogs • Arabinosyl cytosine (ara-c) inhibits the synthesis of d. CDP.

4. Nucleoside analogs • Arabinosyl cytosine (ara-c) inhibits the synthesis of d. CDP.